The in silico trial demonstrated 2X the efficacy of the current treatment (>80% vs 39%); 3X shorter treatment time to cure (6 vs 18 months); 1 drug compared to a 3-drug combo for the standard of care; and preclinical results in shorter time than animal models.
Chemists discover the structures of open and closed states of the channel, which could help the development of antiviral drugs to reduce inflammation
UVA Health researchers have developed a powerful new tool to understand how medications affect men and women differently, and that will help lead to safer, more effective drugs in the future.
Boosting virtual screening with machine learning allowed for a 10-fold time reduction in the processing of 1.56 billion drug-like molecules. Researchers from the University of Eastern Finland teamed up with industry and supercomputers to carry out one of the world’s largest virtual drug screens.
Though antibiotics can treat leprosy, researchers are concerned about the increase in drug-resistant strains. Now, a team reporting in ACS Central Science has begun to understand the role certain immune receptors play in leprosy, which could lead to new types of treatments for this disease.
UC San Diego researchers find a combination of drugs outperformed other treatments in human and mouse models of pancreatic cancer; now urge clinical trial.
According to the newly released “Alzheimer’s Disease Drug Development Pipeline: 2023,” there are currently 187 clinical trials in the Alzheimer’s drug development pipeline – the most ever on record. This momentum is driven in part by greater investment from the pharma industry and a bump in biologic therapies – particularly monoclonal antibodies – that were central to the success of both recent FDA-approved drugs.
The annual report spots trends in clinical trial design and outcome measures, and also investigate the types of agents and biological targets that are being pursued.
Strategies to treat pain without triggering dangerous side effects such as euphoria and addiction have proven elusive. Now scientists at Washington University School of Medicine have identified a potential pathway to pain relief that neither triggers addiction nor causes hallucinations.
A potential drug successfully treats the severe form of nonalcoholic fatty liver disease in non-human primates — bringing scientists one step closer to the first human treatment for the condition that is rapidly increasing around the world, a study suggests. Nonalcoholic steatohepatitis (NASH) causes scarring and inflammation in the liver and is estimated to affect up to 6.5% of the global population.
New research has shown that the blood vessels that feed aggressive brain tumours have receptors that could allow a new type of drug-containing nanoparticle to be used to starve the tumours of the energy they use to grow and spread, and also cause other disruptions to their adapted existence, even killing themselves.
Scientists at St. Jude Children’s Research Hospital showed an effective method to avoid activating a major cellular detoxification receptor to overcome drug resistance and toxicity.
Of all the known genetic risk factors for late-onset Alzheimer’s disease, the strongest is a gene for the protein called ApoE4.
Scientists from The Ohio State University have a new theory about how the building blocks of life – the many proteins, carbohydrates, lipids and nucleic acids that compose every organism on Earth – may have evolved to favor a certain kind of molecular structure.
UC San Diego researchers report that a late-stage, pre-clinical small molecule inhibitor reverses malignant hyper-editing by a protein that promotes silencing of the immune response, metastasis and therapeutic resistance in 20 different cancer types.
The researchers looked at a ubiquitin ligase enzyme named FBXL2, known to degrade proteins at various cellular membrane compartments. They found that by attaching or detaching a fat molecule or lipid to FBXL2 — a process called palmitoylation and de-palmitoylation — they could direct where the FBXL2 went. They also discovered that in order to travel in the aqueous cellular environment for the delivery of lipid-modified FBXL2 to membrane compartments, it used a trafficking protein called PDE6D, which is known to shield the lipid modifications.
By tapping into a cellular garbage disposal function, researchers found they could eliminate STAT5 from cell cultures and mice, setting the stage for potential development as a cancer treatment.
Jaime Merchán, M.D., is the new Translational and Clinical Oncology Research Program co-leader at Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System.
Malaria is a devastating disease, with 247 million cases and 619,000 deaths reported in 2021 alone.
As its 11th-anniversary approaches, the National Primate Research Center of Thailand Chulalongkorn University (NPRCT-CU) and the Primates Enterprise Co., Ltd. are pleased to announce two events in February 2023:
The Alzheimer’s Drug Discovery Foundation (ADDF) and Harrington Discovery Institute at University Hospitals in Cleveland have granted an ADDF-Harrington Scholar Award to Christiane Wrann, PhD, DVM, Associate Professor in Medicine at the Cardiovascular Research Center and the McCance Center for Brain Health at Massachusetts General Hospital and the Harvard Medical School in Boston. Dr. Wrann will receive funding and drug development guidance to help advance her research towards potential new therapies for patients suffering from Alzheimer’s disease.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a cell cycle checkpoint inhibitor with potential therapeutic effects in an ovarian cancer subtype, a telementoring program for French-speaking oncology providers in Africa, insights into the relationship between obesity and immunotherapy side effects, updates to the world’s largest cancer drug discovery knowledgebase, improvements to treatment response by blocking the EGFR pathway, and a novel noninvasive diagnostic test for immunotherapy-related kidney injury.
The ongoing COVID-19 pandemic, caused by the SARS-CoV-2 virus, has been devastating the entire world.
Physician-scientists from Cedars-Sinai Cancer are available for comment on research being presented throughout the San Antonio Breast Cancer Symposium, taking place Dec. 6-10.
Researchers at UC San Diego have identified a new signaling process involving G protein-coupled receptors (GPCRs), a cellular target already exploited by hundreds of diverse drugs. The discovery opens the possibility of new therapies, including for multiple forms of cancer.
The University of Washington has joined the Alliance for Therapies in Neuroscience (ATN), a long-term research partnership between UC San Francisco, UC Berkeley, Genentech (a member of the Roche group) and Roche Holding AG geared to transform the fight against brain diseases and disorders of the central nervous system.
• Just like the real thing. The stem cell–derived interneurons, which play a role in sensations like touch and pain, are indistinguishable from their real-life counterparts in the body.
• Tomorrow’s therapies. In addition to potential treatments for injury-related sensation loss, the discovery could lead to new methods for screening drugs for chronic pain.
• Moving forward. While stem cells from mice were used in the research, scientists are now working to replicate the findings with human cells.
Scientists from the National University of Singapore (NUS) Department of Pharmacy have developed an improved pharmaceutical drug for the treatment of the most common heart rhythm disturbance – atrial fibrillation (AF). This technological breakthrough which could benefit millions of AF patients worldwide.
Texas Biomedical Research Institute Professor Luis Martinez-Sobrido, PhD, an expert in virology, vaccines and antiviral research, has been recruited to collaborate with three of the nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern announced by NIH this spring.
To develop new COVID-19 medications, researchers are working to target nsp13, a protein coronaviruses need to replicate. In ACS Infectious Diseases, researchers describe a new approach to identifying molecules that interfere with this protein, a step toward developing pan-coronavirus antivirals.
With the end of the pandemic seemingly nowhere in sight, scientists are still very focused on finding new or alternative drugs to treat and stop the spread of COVID-19. In a first-of-its-kind study, researchers at the University of New Hampshire have found that using an already existing drug compound in a new way, known as drug repurposing, could be successful in blocking the activity of a key enzyme of the coronavirus, or SARS-CoV-2, which causes COVID-19.
Harrington Discovery Institute® at University Hospitals in Cleveland, Ohio, and its registered UK charity Fund for Cures UK, Ltd. (Fund for Cures UK) have issued a call for proposals for the 2023 Harrington UK Rare Disease Scholar Award. In addition to grant funding, Harrington Discovery provides guidance and oversight in drug development, while intellectual property is retained by the scholar and their institution.
Scientists have reported good news on the pandemic preparedness front: A cocktail of four manufactured antibodies is effective at neutralizing a virus from the Henipavirus family, a group of pathogens considered to be a global biosecurity threat.
Biologists have discovered an aberrant protein that’s deadly to bacteria. The discovery could help scientists unravel the lethal mechanism of certain antibiotics—and potentially point the way to future antibacterial drugs.
Researchers reveal a previously unrealized complexity in cancer development, one that raises concerns and caution about targeting an enzyme popular in oncological treatments.
The Institute of Human Virology at the University of Maryland School of Medicine and MitoPower LLC were awarded an Small Business Innovation Research grant of $6.5 million from the NIH’s National Institute on Alcohol Abuse and Alcoholism to develop a treatment for alcoholic liver disease-associated hepatorenal syndrome.
UC San Diego researchers modify remdesivir, creating oral version that can be taken earlier in COVID-19 diagnoses. In cell and animal studies, revised drug proved effective and safe.
Researchers at the University of Illinois Chicago are developing a potential treatment for COVID-19, thanks to a $6 million technology and therapeutic development award from the U.S. Department of Defense supporting pre-clinical animal studies.
Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery, a journal of the American Association for Cancer Research, in July.
Researchers are the first to model COVID-19 completion versus cessation in clinical trials using machine learning algorithms and ensemble learning. They collected 4,441 COVID-19 trials from ClinicalTrials.gov to build a testbed with 693 dimensional features created to represent each clinical trial. These computational methods can predict whether a COVID-19 clinical trial will be completed or terminated, withdrawn or suspended. Stakeholders can leverage the predictions to plan resources, reduce costs, and minimize the time of the clinical study.
The parasites that cause severe malaria are well-known for the sinister ways they infect humans, but new research may lead to drugs that could block one of their most reliable weapons: interference with the immune response.
UC San Diego School of Medicine researchers discovered that the enzyme RNA polymerase II recognizes and transcribes artificially added base pairs in genetic code, a new insight that could help advance the development of new vaccines and medicines.
Until now, systemic biomarkers to measure exercise effects on brain function and that link to relevant metabolic responses were lacking. A study shows a memory biomarker, myokine Cathepsin B (CTSB), increased in older adults following a 26-week structured aerobic exercise training. The positive association between CTSB and cognition, and the substantial modulation of lipid metabolites implicated in dementia, support the beneficial effects of exercise training on brain function and brain health in asymptomatic individuals at risk for Alzheimer’s.
Researchers identify molecular mechanism for the anti-inflammatory activity of diabetes drug metformin and, in mouse studies, say it prevents lung inflammation in animals infected with SARS-CoV-2, the virus that causes COVID-19.
Researchers have developed a novel continuous-flow microfluidic device that may help scientists and pharmaceutical companies more effectively study drug compounds and their crystalline shapes and structures.
Researchers at the Finnish Center for Artificial Intelligence have developed a machine learning-based method that produces synthetic data, making it possible for researchers to share even sensitive data with one other without privacy concerns.
UC San Diego School of Medicine researchers have developed a new approach — called Surveying Targets by APOBEC-Mediated Profiling (STAMP) — to measure what has until now been largely invisible: how RNA-binding proteins and ribosomes interact with RNA molecules within…
UC Davis researchers develop PsychLight, a sensor that could be used in discovering new treatments for mental illness, in neuroscience research and to detect drugs of abuse.
Texas A&M AgriLife Research will study the function of amino-acid radicals, which are fundamental to both beneficial and harmful chemical reactions in living organisms.
A new SARS-CoV-2 vaccine candidate, developed by giving a key protein’s gene a ride into the body while encased in a measles vaccine, has been shown to produce a strong immune response and prevent SARS-CoV-2 infection and lung disease in multiple animal studies.
New findings, reported in Nature Communications, describe the discovery of a unique dependence of cancer cells on a particular protein, which could lead to desperately needed treatment for hard-to-treat cancers.